-
1
-
-
50849126768
-
Epidemiology and natural history of human PV infections and type-specific implications in cervical neoplasia
-
Bosch X, Burchell AN, Schiffman MH, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Munoz N. Epidemiology and natural history of human PV infections and type-specific implications in cervical neoplasia. Vaccine 2008, 26:K1-K16.
-
(2008)
Vaccine
, vol.26
-
-
Bosch, X.1
Burchell, A.N.2
Schiffman, M.H.3
Giuliano, A.R.4
de Sanjose, S.5
Bruni, L.6
Tortolero-Luna, G.7
Kjaer, S.K.8
Munoz, N.9
-
2
-
-
0036132096
-
Estimates of the world-wide prevalence of cancer for 25 sites in the adult population
-
Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Canc 2002, 97:72-81.
-
(2002)
Int J Canc
, vol.97
, pp. 72-81
-
-
Pisani, P.1
Bray, F.2
Parkin, D.M.3
-
3
-
-
14944385553
-
Global cancer statistics, 2002
-
10.3322/canjclin.55.2.74, 15761078
-
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
-
(2005)
CA Cancer J Clin
, vol.55
, pp. 74-108
-
-
Parkin, D.M.1
Bray, F.2
Ferlay, J.3
Pisani, P.4
-
4
-
-
0023690889
-
Human papillomaviruses and cervical cancer: analysis of histopathologic features associated with different viral types
-
10.1016/S0046-8177(88)80176-X, 2837431
-
Wilczynski SP, Bergen S, Walker J, Liao SY, Pearlman LF. Human papillomaviruses and cervical cancer: analysis of histopathologic features associated with different viral types. Hum Pathol 1988, 19:697-704. 10.1016/S0046-8177(88)80176-X, 2837431.
-
(1988)
Hum Pathol
, vol.19
, pp. 697-704
-
-
Wilczynski, S.P.1
Bergen, S.2
Walker, J.3
Liao, S.Y.4
Pearlman, L.F.5
-
5
-
-
0029041842
-
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group
-
10.1093/jnci/87.11.796, 7791229
-
Bosch X, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman RJ, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995, 87:796-802. 10.1093/jnci/87.11.796, 7791229.
-
(1995)
J Natl Cancer Inst
, vol.87
, pp. 796-802
-
-
Bosch, X.1
Manos, M.M.2
Munoz, N.3
Sherman, M.4
Jansen, A.M.5
Peto, J.6
Schiffman, M.H.7
Moreno, V.8
Kurman, R.J.9
Shah, K.V.10
-
6
-
-
67349271268
-
Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer
-
10.1016/j.yexmp.2009.01.009, 19454268
-
Palmer KE, Jenson AB, Kouokam JC, Lasnik AB, Ghim SJ. Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer. Exp Mol Pathol 2009, 86:224-233. 10.1016/j.yexmp.2009.01.009, 19454268.
-
(2009)
Exp Mol Pathol
, vol.86
, pp. 224-233
-
-
Palmer, K.E.1
Jenson, A.B.2
Kouokam, J.C.3
Lasnik, A.B.4
Ghim, S.J.5
-
7
-
-
33646058566
-
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
-
10.1016/S0140-6736(06)68439-0, 16631880, HPV Vaccine Study group
-
Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G, . HPV Vaccine Study group Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255. 10.1016/S0140-6736(06)68439-0, 16631880, HPV Vaccine Study group.
-
(2006)
Lancet
, vol.367
, pp. 1247-1255
-
-
Harper, D.M.1
Franco, E.L.2
Wheeler, C.M.3
Moscicki, A.B.4
Romanowski, B.5
Roteli-Martins, C.M.6
Jenkins, D.7
Schuind, A.8
Costa Clemens, S.A.9
Dubin, G.10
-
8
-
-
38449112974
-
Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection
-
10.1086/522869, 18008218, FUTURE II Study Group
-
FUTURE II Study Group Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007, 196:1431-1432. 10.1086/522869, 18008218, FUTURE II Study Group.
-
(2007)
J Infect Dis
, vol.196
, pp. 1431-1432
-
-
-
9
-
-
56949087305
-
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
-
10.1016/j.vaccine.2008.09.073, 18930097
-
Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch X, Dillner J, Kurman RJ, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Lu S, Vuocolo S, Hesley TM, Haupt RM, Barr E. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008, 26:6844-6851. 10.1016/j.vaccine.2008.09.073, 18930097.
-
(2008)
Vaccine
, vol.26
, pp. 6844-6851
-
-
Joura, E.A.1
Kjaer, S.K.2
Wheeler, C.M.3
Sigurdsson, K.4
Iversen, O.E.5
Hernandez-Avila, M.6
Perez, G.7
Brown, D.R.8
Koutsky, L.A.9
Tay, E.H.10
Garcia, P.11
Ault, K.A.12
Garland, S.M.13
Leodolter, S.14
Olsson, S.E.15
Tang, G.W.16
Ferris, D.G.17
Paavonen, J.18
Lehtinen, M.19
Steben, M.20
Bosch, X.21
Dillner, J.22
Kurman, R.J.23
Majewski, S.24
Munoz, N.25
Myers, E.R.26
Villa, L.L.27
Taddeo, F.J.28
Roberts, C.29
Tadesse, A.30
Bryan, J.31
Lupinacci, L.C.32
Giacoletti, K.E.33
Lu, S.34
Vuocolo, S.35
Hesley, T.M.36
Haupt, R.M.37
Barr, E.38
more..
-
10
-
-
33847391616
-
Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial
-
10.1097/01.inf.0000253970.29190.5a, 17484215
-
Reisinger KS, Block S, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KE, Sings HL, Lukac S, Alvarez FB, Barr E. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007, 26:201-209. 10.1097/01.inf.0000253970.29190.5a, 17484215.
-
(2007)
Pediatr Infect Dis J
, vol.26
, pp. 201-209
-
-
Reisinger, K.S.1
Block, S.2
Lazcano-Ponce, E.3
Samakoses, R.4
Esser, M.T.5
Erick, J.6
Puchalski, D.7
Giacoletti, K.E.8
Sings, H.L.9
Lukac, S.10
Alvarez, F.B.11
Barr, E.12
-
11
-
-
71649087760
-
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years
-
GlaxoSmithKline Vaccine HPV-007 Study Group
-
Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, Greenacre M, Sgriobhadair A. GlaxoSmithKline Vaccine HPV-007 Study Group Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374:1975-1985. GlaxoSmithKline Vaccine HPV-007 Study Group.
-
(2009)
Lancet
, vol.374
, pp. 1975-1985
-
-
Romanowski, B.1
de Borba, P.C.2
Naud, P.S.3
Roteli-Martins, C.M.4
De Carvalho, N.S.5
Teixeira, J.C.6
Aoki, F.7
Ramjattan, B.8
Shier, R.M.9
Somani, R.10
Barbier, S.11
Blatter, M.M.12
Chambers, C.13
Ferris, D.14
Gall, S.A.15
Guerra, F.A.16
Harper, D.M.17
Hedrick, J.A.18
Henry, D.C.19
Korn, A.P.20
Kroll, R.21
Moscicki, A.B.22
Rosenfeld, W.D.23
Sullivan, B.J.24
Thoming, C.S.25
Tyring, S.K.26
Wheeler, C.M.27
Dubin, G.28
Schuind, A.29
Zahaf, T.30
Greenacre, M.31
Sgriobhadair, A.32
more..
-
12
-
-
43949083734
-
A direct comparison of human PV type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response
-
10.1128/JVI.02482-07, 2395182, 18385253
-
Thönes N, Herreiner A, Schadlich L, Piuko K, Müller M. A direct comparison of human PV type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response. J Virol 2008, 82:5472-5485. 10.1128/JVI.02482-07, 2395182, 18385253.
-
(2008)
J Virol
, vol.82
, pp. 5472-5485
-
-
Thönes, N.1
Herreiner, A.2
Schadlich, L.3
Piuko, K.4
Müller, M.5
-
13
-
-
74249097772
-
Prospects for new human papillomavirus vaccines
-
10.1097/QCO.0b013e328334c0e1, 19926987
-
Stanley M. Prospects for new human papillomavirus vaccines. Curr Opin Infect Dis 2010, 23:70-75. 10.1097/QCO.0b013e328334c0e1, 19926987.
-
(2010)
Curr Opin Infect Dis
, vol.23
, pp. 70-75
-
-
Stanley, M.1
-
14
-
-
49749105995
-
An update of prophylactic human PV L1 virus-like particle vaccine clinical trial results
-
Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human PV L1 virus-like particle vaccine clinical trial results. Vaccine 2011, 26:K53-K61.
-
(2011)
Vaccine
, vol.26
-
-
Schiller, J.T.1
Castellsague, X.2
Villa, L.L.3
Hildesheim, A.4
-
15
-
-
79955476377
-
Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: Immunological problems and future directions
-
10.1016/j.cellimm.2011.03.003, 21477796
-
Chen J, Ni G, Liu XS. Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: Immunological problems and future directions. Cell Immunol 2011, 269:5-9. 10.1016/j.cellimm.2011.03.003, 21477796.
-
(2011)
Cell Immunol
, vol.269
, pp. 5-9
-
-
Chen, J.1
Ni, G.2
Liu, X.S.3
-
16
-
-
67449094695
-
Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines
-
10.1128/JVI.02443-08, 2698533, 19386711
-
Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines. J Virol 2009, 83:6779-6789. 10.1128/JVI.02443-08, 2698533, 19386711.
-
(2009)
J Virol
, vol.83
, pp. 6779-6789
-
-
Bellone, S.1
El-Sahwi, K.2
Cocco, E.3
Casagrande, F.4
Cargnelutti, M.5
Palmieri, M.6
Bignotti, E.7
Romani, C.8
Silasi, D.A.9
Azodi, M.10
Schwartz, P.E.11
Rutherford, T.J.12
Pecorelli, S.13
Santin, A.D.14
-
17
-
-
71749116038
-
Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein
-
10.1016/j.virol.2009.09.012, 19800648
-
Di Bonito P, Grasso F, Mochi S, Petrone L, Fanales-Belasio E, Mei A, Cesolini A, Laconi G, Conrad H, Bernhard H, Dembek CJ, Cosma A, Santini SM, Lapenta C, Donati S, Muratori C, Giorgi C, Federico M. Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. Virology 2009, 395:45-55. 10.1016/j.virol.2009.09.012, 19800648.
-
(2009)
Virology
, vol.395
, pp. 45-55
-
-
Di Bonito, P.1
Grasso, F.2
Mochi, S.3
Petrone, L.4
Fanales-Belasio, E.5
Mei, A.6
Cesolini, A.7
Laconi, G.8
Conrad, H.9
Bernhard, H.10
Dembek, C.J.11
Cosma, A.12
Santini, S.M.13
Lapenta, C.14
Donati, S.15
Muratori, C.16
Giorgi, C.17
Federico, M.18
-
18
-
-
0035873329
-
Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro
-
Rudolf MP, Fausch SC, Da Silva DM, Kast WM. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J Immunol 2001, 166:5917-5924.
-
(2001)
J Immunol
, vol.166
, pp. 5917-5924
-
-
Rudolf, M.P.1
Fausch, S.C.2
Da Silva, D.M.3
Kast, W.M.4
-
19
-
-
0032843743
-
Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA
-
10.1016/S0264-410X(99)00257-1, 10519927
-
Wyatt LS, Whitehead SS, Venanzi KA, Murphy BR, Moss B. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 1999, 18:392-397. 10.1016/S0264-410X(99)00257-1, 10519927.
-
(1999)
Vaccine
, vol.18
, pp. 392-397
-
-
Wyatt, L.S.1
Whitehead, S.S.2
Venanzi, K.A.3
Murphy, B.R.4
Moss, B.5
-
20
-
-
0026009499
-
Complication of intramuscular/subcutaneous immune therapy in severely immune-compromised individuals
-
Picard O, Lebas J, Imbert JC, Bigel P, Zagury D. Complication of intramuscular/subcutaneous immune therapy in severely immune-compromised individuals. J Acquir Immune Defic Syndr 1991, 4:641-643.
-
(1991)
J Acquir Immune Defic Syndr
, vol.4
, pp. 641-643
-
-
Picard, O.1
Lebas, J.2
Imbert, J.C.3
Bigel, P.4
Zagury, D.5
-
21
-
-
46049083590
-
Viral vectors for production of recombinant proteins in plants
-
10.1002/jcp.21423, 18330886
-
Lico C, Chen Q, Santi L. Viral vectors for production of recombinant proteins in plants. J Cell Physiol 2008, 216:366-377. 10.1002/jcp.21423, 18330886.
-
(2008)
J Cell Physiol
, vol.216
, pp. 366-377
-
-
Lico, C.1
Chen, Q.2
Santi, L.3
-
22
-
-
34248172560
-
Optimization of human papillomavirus type 16(HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization
-
10.1099/vir.0.82718-0, 17412974
-
Maclean J, Koekemoer M, Olivier AJ, Stewart D, Hitzeroth II, Rademacher T, Fischer R, Williamson AL, Rybicki EP. Optimization of human papillomavirus type 16(HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J Gen Virol 2007, 88:1460-1469. 10.1099/vir.0.82718-0, 17412974.
-
(2007)
J Gen Virol
, vol.88
, pp. 1460-1469
-
-
Maclean, J.1
Koekemoer, M.2
Olivier, A.J.3
Stewart, D.4
Hitzeroth, I.I.5
Rademacher, T.6
Fischer, R.7
Williamson, A.L.8
Rybicki, E.P.9
-
23
-
-
60349104850
-
An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice
-
10.1186/1743-422X-6-2, 2639544, 19126233
-
Paz De la Rosa G, Monroy-García A, Mora-García Mde L, Peña CG, Hernández-Montes J, Weiss-Steider B, Gómez-Lim MA. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice. Virol J 2009, 6:2. 10.1186/1743-422X-6-2, 2639544, 19126233.
-
(2009)
Virol J
, vol.6
, pp. 2
-
-
Paz De la Rosa, G.1
Monroy-García, A.2
Mora-García Mde, L.3
Peña, C.G.4
Hernández-Montes, J.5
Weiss-Steider, B.6
Gómez-Lim, M.A.7
-
24
-
-
0024264598
-
Fowlpox virus as a vector in non-avian species
-
10.1016/0264-410X(88)90091-6, 2854335
-
Taylor J, Paoletti E. Fowlpox virus as a vector in non-avian species. Vaccine 1988, 6:466-468. 10.1016/0264-410X(88)90091-6, 2854335.
-
(1988)
Vaccine
, vol.6
, pp. 466-468
-
-
Taylor, J.1
Paoletti, E.2
-
25
-
-
0026604536
-
Potential use of nonreplicating vectors as recombinant vaccines
-
10.1016/0264-410X(92)90411-C, 1311489
-
Baxby D, Paoletti E. Potential use of nonreplicating vectors as recombinant vaccines. Vaccine 1992, 10:8-9. 10.1016/0264-410X(92)90411-C, 1311489.
-
(1992)
Vaccine
, vol.10
, pp. 8-9
-
-
Baxby, D.1
Paoletti, E.2
-
26
-
-
14744274585
-
Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry
-
10.1586/14760584.4.1.63, 15757474
-
Skinner MA, Laidlaw SM, Eldaghayes I, Kaiser P, Cottingham MG. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev Vaccines 2005, 4:63-76. 10.1586/14760584.4.1.63, 15757474.
-
(2005)
Expert Rev Vaccines
, vol.4
, pp. 63-76
-
-
Skinner, M.A.1
Laidlaw, S.M.2
Eldaghayes, I.3
Kaiser, P.4
Cottingham, M.G.5
-
27
-
-
4344684061
-
Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors
-
10.1586/14760584.3.4.S75, 15285707
-
Franchini G, Gurunathan S, Baglyos L, Plotkin S, Tartaglia J. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines 2004, 3:S75-S88. 10.1586/14760584.3.4.S75, 15285707.
-
(2004)
Expert Rev Vaccines
, vol.3
-
-
Franchini, G.1
Gurunathan, S.2
Baglyos, L.3
Plotkin, S.4
Tartaglia, J.5
-
28
-
-
0030663697
-
Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors
-
10.1093/jnci/89.21.1595, 9362157
-
Irvine KR, Chamberlain RS, Shulman EP, Rosenberg SA, Restifo NP. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 1997, 89:1595-1601. 10.1093/jnci/89.21.1595, 9362157.
-
(1997)
J Natl Cancer Inst
, vol.89
, pp. 1595-1601
-
-
Irvine, K.R.1
Chamberlain, R.S.2
Shulman, E.P.3
Rosenberg, S.A.4
Restifo, N.P.5
-
29
-
-
0024267575
-
Recombinant fowlpox virus inducing protective immunity in nonavian species
-
10.1016/0264-410X(88)90100-4, 2854338
-
Taylor J, Weinberg R, Languet B, Desmettre P, Paoletti E. Recombinant fowlpox virus inducing protective immunity in nonavian species. Vaccine 1988, 6:497-503. 10.1016/0264-410X(88)90100-4, 2854338.
-
(1988)
Vaccine
, vol.6
, pp. 497-503
-
-
Taylor, J.1
Weinberg, R.2
Languet, B.3
Desmettre, P.4
Paoletti, E.5
-
30
-
-
34248175173
-
Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins
-
10.1186/1750-9378-1-6, 1660559, 17150135
-
Di Bonito P, Grasso F, Mochi S, Accardi L, Donà MG, Branca M, Costa S, Mariani L, Agarossi A, Ciotti M, Syrjänen K, Giorgi C. Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins. Infect Agent Cancer 2006, 1:6-14. 10.1186/1750-9378-1-6, 1660559, 17150135.
-
(2006)
Infect Agent Cancer
, vol.1
, pp. 6-14
-
-
Di Bonito, P.1
Grasso, F.2
Mochi, S.3
Accardi, L.4
Donà, M.G.5
Branca, M.6
Costa, S.7
Mariani, L.8
Agarossi, A.9
Ciotti, M.10
Syrjänen, K.11
Giorgi, C.12
-
31
-
-
0034850163
-
Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes
-
10.1128/JVI.75.19.9201-9209.2001, 114488, 11533183
-
Leder C, Kleinschmidt JA, Wiethe C, Müller M. Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol 2001, 75:9201-9209. 10.1128/JVI.75.19.9201-9209.2001, 114488, 11533183.
-
(2001)
J Virol
, vol.75
, pp. 9201-9209
-
-
Leder, C.1
Kleinschmidt, J.A.2
Wiethe, C.3
Müller, M.4
-
32
-
-
0023002660
-
Conserved TAAATG Sequence at the Transcriptional and Translational Initiation Sites of Vaccinia Virus Late Genes Deduced by Structural and Functional Analysis of the Hindlll H Genome Fragment
-
288911, 3021979
-
Rosel JL, Earl PL, Weir J, Moss B. Conserved TAAATG Sequence at the Transcriptional and Translational Initiation Sites of Vaccinia Virus Late Genes Deduced by Structural and Functional Analysis of the Hindlll H Genome Fragment. J Virol 1986, 60:436-449. 288911, 3021979.
-
(1986)
J Virol
, vol.60
, pp. 436-449
-
-
Rosel, J.L.1
Earl, P.L.2
Weir, J.3
Moss, B.4
-
33
-
-
0037449089
-
Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmid and virus-like particles in prime-boost vaccination protocols against SHIV
-
10.1016/S0264-410X(02)00773-9, 12706695
-
Radaelli A, Zanotto C, Perletti G, Elli V, Vicenzi E, Poli G, De Giuli Morghen C. Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmid and virus-like particles in prime-boost vaccination protocols against SHIV. Vaccine 2003, 21:2052-2064. 10.1016/S0264-410X(02)00773-9, 12706695.
-
(2003)
Vaccine
, vol.21
, pp. 2052-2064
-
-
Radaelli, A.1
Zanotto, C.2
Perletti, G.3
Elli, V.4
Vicenzi, E.5
Poli, G.6
De Giuli Morghen, C.7
-
34
-
-
0030862430
-
Compact, synthetic, vaccinia virus early/late promoter for protein expression
-
Chakrabarti S, Sisler JR, Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997, 23:1094-1097.
-
(1997)
Biotechniques
, vol.23
, pp. 1094-1097
-
-
Chakrabarti, S.1
Sisler, J.R.2
Moss, B.3
-
35
-
-
0027968853
-
Expression of HIV-1 envelope gene by recombinant avipoxvirus
-
10.1016/0264-410X(94)90180-5, 7998420
-
Radaelli A, De Giuli Morghen C. Expression of HIV-1 envelope gene by recombinant avipoxvirus. Vaccine 1994, 12:1101-1109. 10.1016/0264-410X(94)90180-5, 7998420.
-
(1994)
Vaccine
, vol.12
, pp. 1101-1109
-
-
Radaelli, A.1
De Giuli Morghen, C.2
-
36
-
-
0028241837
-
Studies of fowlpox virus recombination in the generation of recombinant vaccines
-
10.1016/0168-1702(94)90078-7, 8079511
-
Parks RJ, Krell PJ, Derbyshire JB, Nagy E. Studies of fowlpox virus recombination in the generation of recombinant vaccines. Virus Res 1994, 32:283-297. 10.1016/0168-1702(94)90078-7, 8079511.
-
(1994)
Virus Res
, vol.32
, pp. 283-297
-
-
Parks, R.J.1
Krell, P.J.2
Derbyshire, J.B.3
Nagy, E.4
-
37
-
-
0345308734
-
U.S. National Institutes of Health, Bethesda, Maryland, USA
-
Rasband WS. U.S. National Institutes of Health, Bethesda, Maryland, USA. 2009, , http://rsb.info.nih.gov/ij/
-
(2009)
-
-
Rasband, W.S.1
-
38
-
-
0030577120
-
Papillomavirus infections-a major cause of human cancers
-
zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta 1996, 1288:F55-F78.
-
(1996)
Biochim Biophys Acta
, vol.1288
-
-
zur Hausen, H.1
-
39
-
-
0032840918
-
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
-
10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F, 10451482
-
Walboomers JM, Jacobs MV, Manos MM, Bosch X, Kummer JA, Shah KV, Snjders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F, 10451482.
-
(1999)
J Pathol
, vol.189
, pp. 12-19
-
-
Walboomers, J.M.1
Jacobs, M.V.2
Manos, M.M.3
Bosch, X.4
Kummer, J.A.5
Shah, K.V.6
Snjders, P.J.7
Peto, J.8
Meijer, C.J.9
Munoz, N.10
-
40
-
-
0026793961
-
HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions
-
10.1016/0042-6822(92)91251-O, 1382345
-
Ghim SJ, Jenson AB, Schlegel R. HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. Virology 1992, 190:548-552. 10.1016/0042-6822(92)91251-O, 1382345.
-
(1992)
Virology
, vol.190
, pp. 548-552
-
-
Ghim, S.J.1
Jenson, A.B.2
Schlegel, R.3
-
41
-
-
0027050013
-
Papillomavirus Li major capsid protein self-assembles into virus-like particles that are highly immunogenic
-
10.1073/pnas.89.24.12180, 50722, 1334560
-
Kirnbauer R, Booy N, Chengt DR, Lowy DR, Schiller JT. Papillomavirus Li major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992, 89:12180-12184. 10.1073/pnas.89.24.12180, 50722, 1334560.
-
(1992)
Proc Natl Acad Sci USA
, vol.89
, pp. 12180-12184
-
-
Kirnbauer, R.1
Booy, N.2
Chengt, D.R.3
Lowy, D.R.4
Schiller, J.T.5
-
42
-
-
0027516212
-
Expression of human PV type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles
-
240261, 8383219
-
Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human PV type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 1993, 67:1936-1944. 240261, 8383219.
-
(1993)
J Virol
, vol.67
, pp. 1936-1944
-
-
Rose, R.C.1
Bonnez, W.2
Reichman, R.C.3
Garcea, R.L.4
-
43
-
-
0028845930
-
Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation
-
10.1016/0264-410X(95)00103-8, 8578834
-
Jansen KU, Rosolowsky M, Schultz LD, Markus HZ, Cook JC, Donnelly JJ, Martinez D, Ellis RW, Shaw AR. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995, 13:1509-1514. 10.1016/0264-410X(95)00103-8, 8578834.
-
(1995)
Vaccine
, vol.13
, pp. 1509-1514
-
-
Jansen, K.U.1
Rosolowsky, M.2
Schultz, L.D.3
Markus, H.Z.4
Cook, J.C.5
Donnelly, J.J.6
Martinez, D.7
Ellis, R.W.8
Shaw, A.R.9
-
44
-
-
72649094063
-
Production of immunogenic human papillomavirus-16 major capsid protein derived virus like particles
-
Patel MC, Patkar KK, Basu A, Mohandas KM, Mukhopadhyaya R. Production of immunogenic human papillomavirus-16 major capsid protein derived virus like particles. Indian J Med Res 2009, 130:213-218.
-
(2009)
Indian J Med Res
, vol.130
, pp. 213-218
-
-
Patel, M.C.1
Patkar, K.K.2
Basu, A.3
Mohandas, K.M.4
Mukhopadhyaya, R.5
-
45
-
-
0029063294
-
Sequence determination of human PV type 6a and assembly of virus-like particles in Saccharomyces cerevisiae
-
10.1006/viro.1995.1283, 7778283
-
Hofmann KJ, Cook JC, Joyce JG, Brown DR, Schultz LD, George HA, Rosolowsky M, Fife KH, Jansen KU. Sequence determination of human PV type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology 1995, 209:506-518. 10.1006/viro.1995.1283, 7778283.
-
(1995)
Virology
, vol.209
, pp. 506-518
-
-
Hofmann, K.J.1
Cook, J.C.2
Joyce, J.G.3
Brown, D.R.4
Schultz, L.D.5
George, H.A.6
Rosolowsky, M.7
Fife, K.H.8
Jansen, K.U.9
-
46
-
-
33747877038
-
Chapter 13: Current findings from prophylactic HPV vaccine trials
-
Koutsky LA, Harper DM. Chapter 13: Current findings from prophylactic HPV vaccine trials. Vaccine 2006, 24:S114-S121.
-
(2006)
Vaccine
, vol.24
-
-
Koutsky, L.A.1
Harper, D.M.2
-
47
-
-
50849122065
-
Immunobiology of human PV infection and vaccination-implications for second generation vaccines
-
Stanley M, Gissmann L, Nardelli-Haefliger D. Immunobiology of human PV infection and vaccination-implications for second generation vaccines. Vaccine 2008, 26:K62-K67.
-
(2008)
Vaccine
, vol.26
-
-
Stanley, M.1
Gissmann, L.2
Nardelli-Haefliger, D.3
-
48
-
-
77956930202
-
Canarypox and fowlpox viruses as recombinant vaccine vectors: a biological and immunological comparison
-
10.1016/j.antiviral.2010.07.005, 20643163
-
Zanotto C, Pozzi E, Pacchioni S, Volonté L, De Giuli Morghen C, Radaelli A. Canarypox and fowlpox viruses as recombinant vaccine vectors: a biological and immunological comparison. Antiviral Res 2010, 88:53-63. 10.1016/j.antiviral.2010.07.005, 20643163.
-
(2010)
Antiviral Res
, vol.88
, pp. 53-63
-
-
Zanotto, C.1
Pozzi, E.2
Pacchioni, S.3
Volonté, L.4
De Giuli Morghen, C.5
Radaelli, A.6
-
49
-
-
0027428414
-
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles
-
238150, 8230414
-
Kirnbauer R, Taub J, Greenstone HL, Roden R, Dürst M, Gissmann L, Lowy DR, Schiller JT. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993, 67:6929-6936. 238150, 8230414.
-
(1993)
J Virol
, vol.67
, pp. 6929-6936
-
-
Kirnbauer, R.1
Taub, J.2
Greenstone, H.L.3
Roden, R.4
Dürst, M.5
Gissmann, L.6
Lowy, D.R.7
Schiller, J.T.8
-
50
-
-
0033696899
-
Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16
-
10.1016/S1097-2765(00)80449-9, 10882140
-
Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 2000, 5:557-567. 10.1016/S1097-2765(00)80449-9, 10882140.
-
(2000)
Mol Cell
, vol.5
, pp. 557-567
-
-
Chen, X.S.1
Garcea, R.L.2
Goldberg, I.3
Casini, G.4
Harrison, S.C.5
-
51
-
-
36049000191
-
Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes
-
10.1016/j.virol.2007.08.004, 17822733
-
Thönes N, Müller M. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes. Virology 2007, 369:375-388. 10.1016/j.virol.2007.08.004, 17822733.
-
(2007)
Virology
, vol.369
, pp. 375-388
-
-
Thönes, N.1
Müller, M.2
-
52
-
-
62249214234
-
Generation of recombinant vaccinia viruses via green fluorescent protein selection
-
10.1089/dna.2008.0792, 2925039, 19182996
-
Popov S, Mirshahidi S, Essono S, Song R, Wang X, Ruprecht RM. Generation of recombinant vaccinia viruses via green fluorescent protein selection. DNA Cell Biol 2009, 28:103-108. 10.1089/dna.2008.0792, 2925039, 19182996.
-
(2009)
DNA Cell Biol
, vol.28
, pp. 103-108
-
-
Popov, S.1
Mirshahidi, S.2
Essono, S.3
Song, R.4
Wang, X.5
Ruprecht, R.M.6
|